The Crohn's disease (CD) candidate gene, protein tyrosine phosphatase non-receptor type 2 (PTPN2), has been shown to regulate epidermal growth factor (EGF)-induced In summary, our data establish a role for PTPN2 in the regulation of EGFR signalling in IECs in response to EGF but not IFNγ. Knock-down of PTPN2 directs EGFR signalling towards increased PI3-K activation and increased suppression of epithelial chloride secretory responses. Moreover, our findings suggest that PTPN2 dysfunction in IECs leads to altered control of intestinal epithelial functions regulated by EGFR.
INTRODUCTION
Phosphorylation and dephosphorylation of specific amino acid residues, such as tyrosine residues, represents a fundamental mechanism for the activation and inactivation of intracellular signalling molecules. Dephosphorylation is carried out by a large number of different protein phosphatases. One important family of such proteins is the protein tyrosine phosphatases. Members of this family play an essential role in the regulation of critical cell signalling events, i.e. proliferation, differentiation and cell survival (46). The gene locus encoding one member of this protein family, protein tyrosine phosphatase non-receptor type 2 (PTPN2), has recently been associated with Crohn's disease (CD), ulcerative colitis (UC) and Type I diabetes (17; 43) . Nevertheless, a functional role for PTPN2, also known as T-cell protein tyrosine phosphatase (TC-PTP), in the pathophysiology of CD or UC has not been identified. Among PTPN2 substrates are the epidermal growth factor receptor (EGFR) (27; 44; 45), the insulin receptor (18) and the signal transducers and activators of transcription 1 and 3, which are important signalling mediators of IFNγ (42; 52; 57). EGFR, also known as ErbB1, is a member of the ErbB receptor family and plays a major role in cell growth and wound repair. EGFR can be activated directly by a member of the EGF family of ligands, or indirectly, by transactivation stimulated by non-EGFR ligands such as carbachol (24) or IFNγ (11; 48), which can occur in an EGFR ligand-dependent orindependent manner (12; 16; 48) . Upon ligand binding, EGFR undergoes autophosphorylation via its tyrosine kinase activity, and forms catalytically active homo-or heterodimers with other ErbB members such as ErbB2 (56). The recruitment of downstream signalling pathways by EGFR depends on the mode of receptor activation (i.e., direct vs. transactivation), the type of receptor dimer formed (homodimer vs. heterodimers), and the pattern of phosphorylation of specific EGFR tyrosine residues (19; 32). Important downstream signalling pathways, 3 originating at the EGFR, include mitogen-activated protein kinases (MAPK), such as extracellular signal-regulated kinase 1/2 (ERK1/2), and phosphatidylinositol 3'-kinase (PI3-K) (5; 32) . In addition to the four major autophosphorylation sites of EGFR, Tyr-1068, Tyr-1086, Tyr-1148 and Tyr-1173, the minor autophosphorylation site Tyr-992 serves as a phospholipase C-γ binding site (34; 50) . While Tyr-1068 is a binding site for the adaptor protein, Grb2, that is involved in the recruitment of MAPK pathways (4; 26) , increased phosphorylation of the residues Tyr-992 and Tyr-1068 has also been associated with elevated activity of PI3-K and Akt (29; 45) . Moreover, our laboratory has previously demonstrated that dephosphorylation of these residues by protein tyrosine phosphatase 1B (PTP1B) mediates differential recruitment of PI3-K by EGF but not G protein-coupled receptor-induced transactivation, even though both mechanisms of EGFR activation lead to inhibition of intestinal epithelial calcium-dependent chloride secretion (24; 28; 46; 47) .
The intestinal epithelium is responsible for the uptake of nutrients and the absorption and secretion of electrolytes and fluids. The driving force for the intestinal secretion of ions and water is the secretion of chloride. Dysregulation of chloride secretion can result in the hypersecretion of chloride and excessive loss of salt and water into the lumen, as occurs in secretory diarrhea (35) , or insufficient chloride secretion as occurs in cystic fibrosis (7) and chronic inflammatory states such as IBD (33; 50) . Therefore, precise regulation of the intestinal epithelial chloride secretion is crucial.
As PTPN2 is involved in regulating both EGFR and IFNγ signalling in non-epithelial systems, this led us to the hypothesis that PTPN2 might be involved in modifying the ability of these pathways to regulate intestinal epithelial chloride secretion. Therefore, the aim of this study was to determine whether PTPN2 regulates EGFR-mediated signalling and, subsequently, epithelial chloride secretion in intestinal epithelial cells. We found that PTPN2 4 promotes EGF, but not IFNγ-induced EGFR activation, and potentiates EGF-induced PI3-K activity and inhibition of intestinal epithelial chloride secretion.
EXPERIMENTAL PROCEDURES
Materials-Human IFNγ (Roche, Mannheim, Germany), recombinant human EGF (Genzyme, Cambridge, MA), AG1478 (Sigma, St. Louis, MO), LY294002 (Sigma), carbachol (Sigma), mouse anti-PTPN2 antibody that detects both the 45kDa and the 48 kDa splice form of PTPN2 (45) (Calbiochem, San Diego, CA), phosphorylation site-specific rabbit anti-EGFR phosphotyrosine-antibodies (Biosource, Camarillo, CA), mouse antiphosphotyrosine PY20-antibody (BD Biosciences, Santa Cruz, CA), rabbit anti-Akt-antibody and mouse anti-EGFR-neutralizing-antibody (clone LA1) (Upstate, Lake Placid, NY), rabbit anti-lamin A/C-antibody, rabbit anti-PI3-Kinase p110-antibody and rabbit anti-ERK1/2-antibody (Santa Cruz Biotechnology, Santa Cruz, CA) and rabbit anti-EGFR-antibody, rabbit anti-phospho-ERK1/2-antibody and rabbit anti-phospho-Akt (Ser 473 )-antibody (Cell Signaling Technologies, Danvers, MA) were obtained from the sources noted. All other reagents were of analytical grade and acquired commercially.
Cell culture-Human colonic T 84 epithelial cells were cultured in a humidified atmosphere with 5% CO 2 as described previously (48) (25) . According to the localization of their receptors, IFNγ (1000 U/ml), EGF (100 ng/ml) and carbachol (100 µM)
were added basolaterally. EGFR-inhibitor AG1478 (10 µM) and PI3-K-inhibitor LY294002 (20 µM) were added bilaterally. transfected with either non-specific control siRNA or specific siRNA targeting PTPN2, and subsequently stimulated with EGF (100 ng/ml) for 5 min. As shown in Figure 1a , PTPN2-specific siRNA caused a dramatic reduction of PTPN2 protein expression. Densitometric analysis revealed a maximal decrease in PTPN2 protein of 93 ± 3 % (Fig. 1a) . Equivalent levels of the loading control, lamin A/C, confirmed that the transfection had no non-specific effects on cellular protein expression ( Having shown that PTPN2 knock-down promotes EGF-induced EGFR tyrosine phosphorylation, we next investigated which specific EGFR tyrosine residues are targeted by the phosphatase. T 84 cells were transfected either with control siRNA or PTPN2 siRNA, treated with EGF (100 ng/ml) for 5 min and analyzed for EGFR phosphorylation patterns using phosphotyrosine-specific antibodies by Western blotting. As shown in Figure 2a , EGF treatment alone significantly increased phosphorylation of Tyr-992, and this effect was further enhanced in PTPN2-deficient cells (144 ± 16 % vs. 183 ± 9 %; p<0.05). Interestingly, loss of PTPN2 led to an increase in baseline EGFR Tyr-992 phosphorylation to a similar extent as EGF treatment of PTPN2-competent cells. However, this effect was statistically not significant ( Fig. 2b) . While phosphorylation of Tyr-1068 was also induced in response to EGF and further enhanced by PTPN2 knock-down (160 ± 6 % vs. 254 ± 26 %; p<0.001; Fig. 2c ),
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baseline Tyr-1068 phosphorylation levels were not altered in PTPN2-deficient cells (Fig. 2d ).
In contrast, PTPN2 knock-down did not significantly affect baseline phosphorylation or EGFinduced phosphorylation of Tyr-1148 ( These data demonstrate that PTPN2 activity selectively modulates the pattern of EGFR tyrosine phosphorylation and may, subsequently, play a role in the regulation of downstream signalling originating at the EGFR.
PTPN2 regulates EGF-induced PI3-K, but not ERK1/2 activation.

Having demonstrated that PTPN2 likely dephosphorylates EGFR phospho-residues
Tyr-992 and Tyr-1068, we next set out to study the functional consequences of this finding.
The selective activation and recruitment of pathways downstream of EGFR depends on the tyrosine phosphorylation pattern of the receptor (32 EGF activation of the ERK-isoforms (ERK1/2) of the MAPK family is well described (38) .
To test whether PTPN2 might also be involved in the regulation of EGF-induced activation of MAPK signalling, we examined whether EGF-induced phosphorylation of ERK1/2 was altered in PTPN2 siRNA-transfected T 84 cells. Although ERK1/2 phosphorylation was strongly induced in EGF-treated control cells this effect was not altered by PTPN2 knockdown (Fig. 5 ). These data indicate that PTPN2 is involved in regulating the link of EGFR to the PI3-K/Akt pathway, but not ERK, in response to the EGF.
Loss of PTPN2 enhances EGF inhibition of Ca
2+
-dependent chloride secretion. with non-specific control siRNA (2.6 ± 0.6 vs. 4.9 ± 1.1 μA/cm 2 ; Fig. 6a ). Corresponding to the elevated PI3-K activity in EGF-treated PTPN2-deficient cells (c.f. Fig. 4a ), the inhibitory effect of EGF on Ca
-dependent Cl -secretion was further enhanced in PTPN2-deficient cells (2.0 ± 0.5 vs. 6.2 ± 1.6 μA/cm 2 ; Fig. 6a ). The admittedly rather small I sc responses could be due to the fact that cells were grown for only 4 days after transfection in order to maintain a PTPN2-deficient phenotype. Therefore, the T 84 cells were likely not able to develop as tight a monolayer as "conventionally" grown T 84 cells that are usually seeded for 10-14 days before conducting electrophysiologic experiments. This was confirmed by measuring the conductance of these T 84 monolayers (Fig. 6b) . As expected, the mean conductance values of the transfected T 84 monolayers was about 8-fold higher than those across "conventionally" monolayers for 72 h with either IFNγ (1000 U/ml), the pharmacologic EGFR inhibitor AG1478 (10 µM), or both in combination. As shown in Fig. 6d , IFNγ treatment significantly decreased the TER across T 84 monolayers, while EGFR inhibition alone had no effect on TER (p<0.001; n=4). Interestingly, co-incubation with AG1478 was not sufficient to prevent the (36) . Using a previously validated concentration of IFNγ (1000 U/ml) (49), IFNγ increased phosphorylation of EGFR in cells transfected with control siRNA (Fig. 7a) . However, phospho-EGFR levels of IFNγ-treated PTPN2-deficient cells did not differ significantly from the respective controls or from the level of IFNγ-induced EGFR phosphorylation relative to total EGFR in PTPN2-competent cells (Fig. 7a ). In accordance with our previous results (Fig.   1c ), baseline EGFR phosphorylation levels did not significantly differ under these conditions (Fig. 7b) subunit of PI3-K in either control siRNA-transfected or in PTPN2 siRNA-transfected cells (Fig. 7d) . Similarly, loss of PTPN2 had no effect on IFNγ-induced activation of ERK1/2 by 24 h treatment (Fig. 7e ). These data demonstrate that PTPN2 regulates EGFR expression, but not EGFR activation or signalling in response to IFNγ.
DISCUSSION
In this study, we demonstrate that the CD candidate gene, PTPN2, regulates EGFR- The proinflammatory cytokine IFNγ inhibits chloride secretion (9; 41) and also activates EGFR in IECs. However, the inhibitory effect on Cl -secretion could not be reversed by inhibition of EGFR kinase activity (49). Interestingly, and in contrast to EGF-induced EGFR phosphorylation, PTPN2 knock-down did not affect IFNγ-induced phosphorylation of EGFR in our studies. Since IFNγ did not increase p110 association with EGFR, and this was also unaltered in PTPN2-deficient cells, we conclude that the PI3-K/Akt pathway is likely not activated by IFNγ at the time points tested, which is in agreement with observations by other groups (10; 30). In addition, although IFNγ treatment induced phosphorylation of ERK1/2, this was not altered by PTPN2 knock-down. These data suggest that PTPN2 regulates only EGFR-mediated PI3-K, but not ERK1/2 signalling and is likely not recruited to the EGFR in response to IFNγ. However, PTPN2 does appear to regulate the expression of EGFR in response to the cytokine. Intriguingly, PTPN2 knockdown had the opposite to anticipated effect in that it reduced rather than enhanced the effect of IFNγ on EGFR expression.
Although the molecular mechanisms responsible for this have still to be determined, this finding could possibly be of significance for EGFR signalling outcomes in the joint setting of reduced PTPN2 expression or activity, and active inflammation. These questions are being addressed in ongoing investigations by our group. In agreement with our previous work
showing EGFR kinase-independent effects of IFNγ on EGFR activation and inhibition of Cl -secretion, we also found no involvement of EGFR kinase activity in the IFNγ-induced decrease of intestinal epithelial barrier function. These data support our hypothesis that PTPN2 plays a more involved role in regulating EGFR signalling, and consequent outcomes, in response to EGF activation rather than IFNγ induced EGFR activation.
In summary, our data establish a role for PTPN2 in the regulation of EGFR signalling 
